Perrigo Company plc (NYSE:PRGO) Shares Sold by Janney Montgomery Scott LLC

Janney Montgomery Scott LLC lowered its stake in Perrigo Company plc (NYSE:PRGO - Free Report) by 20.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 72,126 shares of the company's stock after selling 18,498 shares during the period. Janney Montgomery Scott LLC owned approximately 0.05% of Perrigo worth $2,022,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Cedar Wealth Management LLC grew its holdings in shares of Perrigo by 2.1% in the fourth quarter. Cedar Wealth Management LLC now owns 21,966 shares of the company's stock worth $565,000 after purchasing an additional 450 shares during the last quarter. Amalgamated Bank lifted its position in Perrigo by 0.8% during the fourth quarter. Amalgamated Bank now owns 64,086 shares of the company's stock valued at $1,648,000 after acquiring an additional 522 shares during the last quarter. Fox Run Management L.L.C. boosted its position in shares of Perrigo by 5.1% in the 4th quarter. Fox Run Management L.L.C. now owns 11,381 shares of the company's stock worth $293,000 after purchasing an additional 548 shares in the last quarter. Snowden Capital Advisors LLC boosted its holdings in Perrigo by 3.6% in the fourth quarter. Snowden Capital Advisors LLC now owns 24,337 shares of the company's stock worth $626,000 after acquiring an additional 842 shares in the last quarter. Finally, Fifth Third Bancorp increased its holdings in shares of Perrigo by 62.0% during the first quarter. Fifth Third Bancorp now owns 2,218 shares of the company's stock valued at $62,000 after acquiring an additional 849 shares in the last quarter. Hedge funds and other institutional investors own 95.91% of the company's stock.

Perrigo Stock Performance

Shares of PRGO traded up $0.19 during trading hours on Monday, hitting $26.73. The stock had a trading volume of 903,109 shares, compared to its average volume of 1,454,320. The firm has a 50-day moving average price of $26.35 and a 200 day moving average price of $25.99. Perrigo Company plc has a fifty-two week low of $23.14 and a fifty-two week high of $30.93. The firm has a market capitalization of $3.67 billion, a price-to-earnings ratio of -20.40 and a beta of 0.46. The company has a debt-to-equity ratio of 0.82, a quick ratio of 1.28 and a current ratio of 2.36.

Perrigo (NYSE:PRGO - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $0.60 earnings per share for the quarter, topping analysts' consensus estimates of $0.56 by $0.04. Perrigo had a negative net margin of 4.16% and a positive return on equity of 8.93%. The business had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1.09 billion. During the same quarter in the prior year, the firm posted $0.29 earnings per share. The company's revenue was down 3.5% compared to the same quarter last year. As a group, research analysts anticipate that Perrigo Company plc will post 2.56 EPS for the current year.

Perrigo Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 17th. Shareholders of record on Friday, May 30th were issued a $0.29 dividend. This represents a $1.16 annualized dividend and a yield of 4.34%. The ex-dividend date was Friday, May 30th. Perrigo's payout ratio is currently -88.55%.

Analysts Set New Price Targets

Separately, Wall Street Zen downgraded Perrigo from a "buy" rating to a "hold" rating in a research report on Friday. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the company's stock. According to data from MarketBeat, Perrigo has a consensus rating of "Hold" and an average target price of $33.00.

Perrigo Profile

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.